Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ENPP3 | O14638 | 2/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL794078 | 0.87 | MAPT (0.50) | MAPTCA9LMNAGRM4KDR | |
| SCHEMBL788182 | 0.86 | KDR (0.48) | MAPTCA9LMNAGRM4KDR | |
| SCHEMBL793720 | 0.85 | MAPT (0.52) | MAPTCA9LMNAGRM4KDR | |
| SCHEMBL793766 | 0.83 | MAPT (0.47) | MAPTCA9LMNAGRM4KDR | |
| SCHEMBL793582 | 0.83 | MAPT (0.46) | MAPTCA9LMNAGRM4KDR | |
| SCHEMBL793951 | 0.81 | MAPT (0.49) | MAPTCA9LMNAKDRTP53 | |
| SCHEMBL793603 | 0.79 | MAPT (0.47) | MAPTCA9LMNAGRM4KDR | |
| SCHEMBL794154 | 0.78 | MAPT (0.47) | MAPTCA9LMNAGRM4KDR | |
| SCHEMBL793250 | 0.76 | MAPT (0.49) | MAPTCA9LMNAKDRENPP3 | |
| SCHEMBL793756 | 0.76 | CA9 (0.50) | MAPTCA9LMNAKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165440-A1 | JAK1 Inhibitors | EXELIXIS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165440-A1 | JAK1 Inhibitors | JAK1, JAK2, JAK3 | MAPT 2899/4885CA9 4203/4885LMNA 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.